Modality
Radioligand
MOA
Menini
Target
JAK2
Pathway
Cell Cycle
SCD
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
~May 2020
→ ~Aug 2021
Phase 3
~Nov 2021
→ ~Feb 2023
NDA/BLA
~May 2023
→ ~Aug 2024
Approved
Nov 2024
→ Oct 2025
ApprovedCurrent
NCT07161769
2,883 pts·SCD
2024-11→2025-10·Active
2,883 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-10-066mo agoPh3 Readout· SCD
Trial Timeline
2025Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2025-10-06 · 6mo ago
SCD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07161769 | Approved | SCD | Active | 2883 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |